|
Method for synthesis of 4beta-amino-4'-demethyl-4-desoxypodophyllotoxin |
|
IPC classes for russian patent Method for synthesis of 4beta-amino-4'-demethyl-4-desoxypodophyllotoxin (RU 2405787):
Pest control agent / 2405310
Invention describes compositions for use as a pest control agents containing a compound of formula (I), or a salt of the said compound, acceptable in agriculture or horticulture, as an active ingredient or carrier which is acceptable in agriculture or horticulture: [chemical formula 1] , where Het1 denotes an optionally substituted pyridyl, R1 denotes hydroxyl, optionally substituted C1-6alkylcarbonyloxy, optionally substituted C1-6alkyloxy, or oxo, in the absence of a hydrogen atom in position 13, or the bond between position 5 and position 13 is a double bond in the presence of R1 and a hydrogen atom in position 5, R2 denotes hydroxyl, optionally substituted C1-18alkylcarbonyloxy, benzoyloxy or C1-6alkylsulphonyloxy, R3 denotes a hydrogen atom, hydroxyl, optionally substituted C1-18alkylcarbonyloxy, benzoyloxy, C1-6alkylsulphonyloxy, benzoylsulphonyloxy, imidazolylthiocarbonyloxy, R4 denotes a hydrogen atom, hydroxyl, optionally substituted C1-18alkylcarbonyloxy, C2-6alkenylcarbonyloxy, C2-6alkynylcarbonyloxy, benzoyloxy, C1-6alkylsulphonyloxy, benzoylsulphonyloxy, benzyloxy, C1-6alkyloxy, C1-6alkyloxy-C1-6alkyloxy, C1-6alkylthio-C1-6alkyloxy, C1-6alkyloxy-C1-6alkyloxy-C1-6alkyloxy, C1-6alkyloxycarbonyloxy, C1-6alkylaminocarbonyloxy, tetrahydropyranyloxy, a saturated or unsaturated five- or six-member heterocyclic carbonyloxy, where the said heterocyclic part is selected from a group comprising pyridyl, thienyl, thiazolylpyrazinyl and imidazolyl, optionally substituted tieno[3,2-b]pyridylcarbonyloxy, 1H-indolylcarbonyloxy, imidazolylthiocarbonyloxy, or oxo, in the absence of a hydrogen atom in position 7, provided that the compound, where Het1 denotes 3-pyridyl, R1 denotes hydroxyl and each of R2, R3 and R4 is acetyloxy, is excluded. Disclosed composition is also used in hemipterous pest control.
Method for synthesis of epothilone derivatives, novel epothilone derivatives, as well as novel intermediate compounds for realising said method and synthesis methods thereof / 2404985
Invention relates to novel epothilone derivatives of formula (8) , to synthesis method thereof and use thereof to obtain compounds of formula (9) , as well as to novel intermediate compounds for realising said method and synthesis methods thereof. The abbreviation P in said general structural formulae denotes a protective group of a functional hydroxyl selected from silyl protective groups, R2 denotes a 5-member heteroaryl containing N and S as heteroatoms, optionally substituted with C1-C6 alkyl, and R1 denotes methyl.
Dibenzylidene sorbitol (dbs) based compounds, composition and method of using said compounds / 2401271
Invention relates to novel dibenzylidene sorbitol (DBS) compounds of formula 1: , in which R1 and R2 are independently selected from a group consisting of CH3CH2CH2- and CH3CH2CH2O-; and in which R3 is independently selected from -CH2CH2CH3 and -CH2-CH=CH2 groups. According to one version, this invention pertains to a disubstituted DBS based compound having an allyl or propyl group as a substitute at the first carbon atom in the sorbitol chain. The present invention also relates to compositions containing such DBS based compounds and preparation methods thereof.
Tricyclic compounds of benzopyran as antiarrhythmic agents / 2380370
Invention relates to benzopyran derivatives of formula or
Method for production of (3r, 3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1- benzyl-2-hydroxypropylurethane / 2376308
Production of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylurethane is carried out with application of intermediate compound 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(isobutyl)benzenesulfonamide. (3R,3aS,6aR)- hexahydrofuro [2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylurethane is applicable, in particular as inhibitor of HIV protease.
Derivatives of 2-(hereto)aryl-substituted tetrahydroquinolines / 2375354
There are presented compounds of formula I wherein W, R, R1, R2, R3, R4, R5, R6 and R7 have values specified in cl. 1 of the patent claim, and to method for making these compounds, a based medicinal agent used for treating conditions affected by inhibition, regulation and/or modulation of mitotic motor protein Eg5, to a mixture and application of said compounds for making the medicinal agent.
Method of polyolefin composition nucleation by acetal compounds / 2348637
Invention concerns method of polyolefin composition nucleation by mixing the composition with compound of the structural formula: , where: n is 0, 1 or 2; Ar1 and Ar2 are independently selected out of group including non-substituted aryl groups and aryl groups substituted by substitutes selected out of group including alkyl groups, alkenyl groups, alkinyl groups, alkoxy groups, carboxy groups and halogens; and R is selected out of group including alkenyl groups, alkyl groups, alkoxy groups, hydroxyalkyl groups and alkylhalide groups. Also invention claims the compound itself, method of its obtaining and moulded or cast polyolefin article including this compound.
Method of obtaining epotilone derivatives / 2343155
Method ensures carrying out aldole condensation in presence of epoxide mesilate and tosilate, using auxiliary chiral sultamic group as carboxyl- protecting group, as a result, reduction and oxidation stages, requiring extra time, before carrying out final stage of macrolactonisation are excluded. Introduction of epoxidic group at early stages of method allows also excluding stage of epoxilation of more complex intermediate compounds at further stages of process.
New tetracyclic compounds containing heteroatom, used as selective modulators of oestrogen receptors / 2331645
Invention pertains to new tetracyclic compounds containing a heteroatom. The compounds can be used in treating and/or prevention of disorders, associated with oestrogen depletion, such as hot flash, vaginal dryness, osteopenia and osteoporosis; sensitive cancerous diseases hormone and hyperplasia of the lacteal gland, endometrium, cervix uteri and prostate; endometriosis, uterus fibrosis and osteoarthritis, and as contraceptive agents, used either separately or combined with progestogen or a progestogen antagonist.
Analogs of himbacin, their using and pharmaceutical composition based on thereof possessing property of thrombin receptor antagonist / 2319704
Invention relates to heterocycle-substituted tricyclic compounds of the formula (I): or their pharmaceutically acceptable salts wherein R means hydrogen atom; R1 and R2 are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R3 means hydrogen atom; n1 and n2 = 0-3 independently under condition that they both do not mean 0; Het means pyridyl wherein pyridyl is added to B through cyclic carbon atom and it comprises from 1 to 4 substitutes (W) chosen independently from group comprising -NR4R5, -NHCOR26, -NHSO2R16; R21 means aryl and R21 means heteroaryl wherein heteroaryl represents furyl, thienyl, pyridyl, thiazolyl, pyrrolidinyl, azethidinyl; R4 and R5 mean hydrogen atom or alkyl comprising 1-6 carbon atoms, or R4 and R5 mean in common -(CH2)3-, -(CH2)4-, -(CH2)5- or -(CH2)2NR7-(CH2)2- wherein R7 means hydrogen atom or alkyl comprising 1-6 carbon atoms; R8, R, R10 and R11 mean hydrogen atom; B means -(CH2)n4CR12=CR12a(CH2)n5 wherein n4 and n5 = 0-2 independently; R12 and R12a are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R21 means from 1 to 3 substitutes chosen independently from group comprising hydrogen atom, trifluoromethyl, trifluoromethoxy, halogen atom, cyano, alkyl comprising 1-6 carbon atoms, alkoxy group comprising 1-6 carbon atoms, or -CR29(=NOR28); R22 means -COR23, -S(O)R31, -S(O)2R31 or -COOR27; R23 means cycloalkyl comprising 3-7 carbon atoms, (C3-C7)-cycloalkyl-(C1-C6)-alkyl, cycloalkyl comprising 3-7 carbon atoms containing from 1 to 3 substitutes chosen from group comprising halogen atom, (C1-C3)-alkoxy-(C1-C3)-alkyl, hydroxy group and alkoxy group comprising 1-6 carbon atoms, aryl, aryl-(C2-C6)-alkyl; R27 means alkyl comprising 1-6 carbon atoms, phenyl or benzyl; R28 and R29 are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R31 means alkyl comprising 1-6 carbon atoms, halogenalkyl comprising 1-6 carbon atoms, aryl, aryl-(C1-C6)-alkyl. Also, invention relates to pharmaceutical compositions containing these substances and their using for preparing a drug used in treatment of thrombosis, atherosclerosis, restenosis, hypertension, stenocardia, arrhythmia, heart failure and cancer.
Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5- yl- sulfonyl)(isobu tyl)amino]-1-benzyl-2-hydroxypropyl}carbamate, pharmaceutical composition based on thereof, methods for inhibition and method for treatment / 2247123
Invention relates to new bis-tetrahydrofuranbenzodioxolyl sulfonamide compounds of the formula (I): , its salts, stereoisomers and racemates that are effective inhibitors of protease activity. Also, invention relates to pharmaceutical preparations, methods for inhibition of retrovirus proteases, in particular, to resistant retrovirus proteases, to many drugs, methods for treatment and prophylaxis of infection or disease associated with retrovirus infection in mammals and to methods for inhibition of retrovirus replication. Invention provides preparing new derivatives of bis-tetrahydrofuranbenzodioxalyl sulfonamides eliciting the valuable pharmaceutical properties.
Taxane pentacyclic compound and antitumor agents based on thereof / 2257387
Invention relates to a new pentacyclic compound derivative of taxane represented by the formula:
Method for preparing derivatives of baccatin iii / 2264394
Invention relates to a novel method for preparing 14β-hydroxy-1,4-carbonate-desacetylbaccatin III and intermediate substances used in preparing new derivatives of taxane and possessing an antitumor activity. Method involves the following stages: a) protection of hydroxyls at positions 7 and 10 in 10-desacetylbaccatin III wherein R and R1 are taken among hydrogen atom, (C1-C10)-alkyl or aryl, (C1-C10)-alkyl- or aryl-carbonyl, trichloroacetyl, (C1-C4)-trialkylsilyl; preferably, when R and R1 are similar then they represent trichloroacetyl; when they are different then, preferably, R represents trichloroacetyl and R1 represents acetyl; or R represents triethyl or trimethylsilyl and R1 represents acetyl; b) two-stage oxidation to yield a derivative oxidized to carbonyl at position 13 and hydroxylated at position 14; c) carboxylation of vicinal hydroxyls at positions 1 and 14 to yield 1,14-carbonate derivative; d) reduction of carbonyl at position 13; e) removal of protective groups at positions 7 and 10. Also, invention relates to intermediate substances. Invention provides preparing intermediate substances used in synthesis of taxane.
Method for preparing 1,11-dialkyl-3,5-dihydrofuro-[2',3':3,4]-cyclohepta[c]isochromens / 2282633
Invention relates to a method for synthesis of new compounds, namely, 1,11-dialkyl-3,5-dihydrofuro-[2',3':3,4]-cyclohepta[c]isochromens of the formula: (Ia-f): wherein (Ia): R means hydrogen atom (H); R1 means hydrogen atom (H); (Ib): R means bromine atom (Br); R1 means hydrogen atom (H); (Ic): R means chlorine atom (Cl); R1 means hydrogen atom (H); (Id): R means hydrogen atom (H); R1 means bromine atom (Br): (Ie): R means hydrogen atom (H); R1 means chlorine atom (Cl); (If): R means methoxy-group (-OCH3); R1 means hydrogen atom. Method involves formation of condensed tetracyclic system as result of the successive recyclization reactions of furan ring of derivatives of 2-bis-(5-methyl-2-furylmethyl)phenylmethanol and the secondary cyclization of formed isochromen ketone in boiling of solution containing derivatives of 2-bis-(5-methyl-2-furylmethyl)phenylmethanol of the formula: in ethanol medium in the presence of hydrogen chloride alcoholic solution for 15-40 min. Invention provides synthesis of new derivatives of isochromens possessing the potential anti-inflammatory activity.
Crystals of taxane derivatives and method for their preparing / 2284328
Invention relates to a novel crystalline form of (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-9,10-[(1S)-2-(dimethylamino)ethylideneoxy]-5,20-epoxy-1-hydroxytax-11-ene-13-yl-(2R,3S)-3-(tert.-butoxycarbonylamino)-3-(3-fluoro-2-pyridyl)-2-hydroxypropionate that shows the diffraction picture of roentgen rays in powder with characteristic peaks at diffraction angles (θ)= 6.2o, 10.3o, 10.7, 11.4o and 12.0, and a method for its preparing. Method involves carrying out the crystallization step by using organic solvent chosen from group consisting of ketone type solvent, nitrile solvent type and their mixture, or mixture of said solvent and water. Also, invention relates to an antitumor agent based on the prepared crystalline form. Invention provides the stable quality of a medicinal agent based on its lower hygroscopicity.
Method for isolating epotilons from reaction mixture and desorption from synthetic resin (variants), using low-polar or nonpolar solvent for realization of method / 2285007
Invention relates to a method for isolation of epotilons used in medicine in treatment of cancer diseases. Method for desorption of epotilons A, B, D and/or E from synthetic resin is based on using low-polar or nonpolar solvent chosen from the group comprising (lower)-alkyl halides and aromatic solvents, or mixture of two or more amount of such solvents wherein prefix "(lower)" means that radical comprises up to 7 carbon atoms. Used aromatic solvent is chosen from the group including naphthalene, benzene or naphthalene and benzene substituted with one or some substitutes chosen from the following group: (lower)-alkyl, (lower)-alkoxy-group, halogen atom, nitro-group and (lower)-alkoxy-(lower)-alkyl wherein prefix "(lower)" means that radical comprises up to 7 carbon atoms. Solvent is removed to the required level but up to preparing a dry residue preferably. If necessary, residue is dissolved in mixture alcohol/hydrocarbon in the corresponding volume ratio. Alcoholic phase is evaporated until dry and then alcoholic extract is crystallized from mixture alcohol and hydrocarbon. Then formed crystallized product is dissolved in mixture nitrile/water but preferably in mixture acetonitrile/water taken in the ratio = 2:3 (vol./vol.). Formed solution is applied on column (if necessary, after separation for some distillates) for preparative chromatography in reversed phase followed by elution with mixture nitrile/water, removing nitrile and extraction of an aqueous phase with ester. Ester extract is evaporated and formed product is subjected for crystallization. Method for preparing epotilons A, B, D and/or E from resin or reaction mixture involves the following steps: (a) desorption of epotilons with low-polar or nonpolar solvent chosen from the group including (lower)-alkyl halides and aromatic solvents, or mixture of two or more amount of such solvents being the desorption step can be repeated up to achievement of the more complete desorption; (b) removal of solvent used in desorption from formed solutions by evaporation; (c) optional crystallization of epotilon(s) after desorption and first of all for crystallization of epotilon B by addition of mixture of alcohol with hydrocarbon and the following evaporation of alcoholic phase until dry and crystallization of epotilon B from the corresponding mixture of solvents; (d) (obligatory step) separation of epotilons by method of chromatography in reversed phase and the following dissolving a residue obtained in previous step in suitable solvent, elution with mixture nitrile/water and removing nitrile from epotilon-containing fractions by evaporation. If necessary, water remained with epotilon is extracted with ester followed by evaporation of epotilon-containing ester phase until dry; (e) optional purification by adsorption chromatography method, and final recrystallization of purified epotilon from corresponding solvents or mixture of solvents. If necessary, in this process between each step formed solutions or suspensions are concentrated, and/or liquid or solid components are separated of one another. Separation of epotilons A and B is carried out by chromatography method based on a mobile layer modeling. Invention provides simplifying methods for preparing large amounts of epotilons for satisfying requirement in these agents.
Tetracyclic heterocompounds as estrogen receptor modulating agents / 2305099
Invention relates to novel tetracyclic heterocompounds of the formula (I): wherein X, Y, Z, R1 - R4, n and m has values given in the invention description and used as selective modulating agents for estrogen receptors. Also, invention relates to a method for synthesis of these compounds and pharmaceutical compositions comprising thereof, and their using in treatment and/or prophylaxis of disorders mediated by one or more estrogen receptors. Proposed compounds are useful in treatment and/or prophylaxis of disorders associated with depleting estrogen and comprising such disorders as rush of blood, vaginal dryness, osteopenia and osteoporosis, hormone-dependent cancer and hyperplasia of breast, endometrium, uterus cervix and prostate, endometriosis, uterus fibroma, osteoarthritis that can be used as contraceptive agents both separately and in combination with progestogen or progestogenous antagonist.
C-glycoside derivatives and their salts / 2317288
Invention relates to novel compounds representing C-glycoside derivatives and their salts of the formula: wherein ring A represents (1) benzene ring; (2) five- or six-membered monocyclic heteroaryl ring comprising 1, 2 or 4 heteroatoms chosen from nitrogen (N) and sulfur (S) atoms but with exception of tetrazoles, or (3) unsaturated nine-membered bicyclic heterocycle comprising 1 heteroatom representing oxygen atom (O); ring B represents (1) unsaturated eight-nine-membered bicyclic heterocycle comprising 1 or 2 heteroatoms chosen from N, S and O; (2) saturated or unsaturated five- or six-membered monocyclic heterocycle comprising 1 or 2 heteroatoms chosen from N, S and O; (3) unsaturated nine-membered bicyclic carbocycle, or (4) benzene ring; X represents a bond or lower alkylene wherein values for ring A, ring B and X correlate so manner that (1) when ring A represents benzene ring then ring B is not benzene ring, or (2) when ring A represents benzene ring and ring B represents unsaturated eight-nine-membered bicyclic heterocycle comprising 1 or 2 heteroatoms chosen from N, S and O and comprising benzene ring or unsaturated nine-membered bicyclic carbocycle comprising benzene ring then X is bound to ring B in moiety distinct from benzene ring comprised in ring B; each among R1-R4 represents separately hydrogen atom, -C(=O)-lower alkyl or lower alkylene-aryl; each R5-R11 represents separately hydrogen atom, lower alkyl, halogen atom, -OH, =O, -NH2, halogen-substituted lower alkyl-sulfonyl, phenyl, saturated six-membered monocyclic heterocycle comprising 1 or 2 heteroatoms chosen from N and O, lower alkylene-OH, lower alkyl, -COOH, -CN, -C(=O)-O-lower alkyl, -O-lower alkyl, -O-cycloalkyl, -O-lower alkylene-OH, -O-lower alkylene-O-lower alkyl, -O-lower alkylene-COOH, -O-lower alkylene-C(=O)-O-lower alkyl, -O-lower alkylene-C(=O)-NH2, -O-lower alkylene-C(=O)-N-(lower alkyl)2, -O-lower alkylene-CH(OH)-CH2(OH), -O-lower alkylene-NH, -O-lower alkylene-NH-lower alkyl, -O-lower alkylene-N-(lower alkyl)2, -O-lower alkylene-NH-C(=O)-lower alkyl, -NH-lower alkyl, -N-(lower alkyl)2, -NH-lower alkylene-OH or NH-C(=O)-lower alkyl. Indicated derivatives can be used as inhibitor of co-transporter of Na+-glucose and especially as a therapeutic and/or prophylactic agent in diabetes mellitus, such as insulin-dependent diabetes mellitus (diabetes mellitus 1 type) and non-insulin-dependent diabetes mellitus (diabetes mellitus 2 type), and in diseases associated with diabetes mellitus, such as insulin-resistant diseases and obesity.
Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants) / 2318818
Invention relates to novel azaheterocycles of the general formula (I): possessing inhibitory effect on activity of tyrosine kinase and can be used in treatment of different diseases mediated by these receptors. In compound of the general formula (1) W represents azaheterocycle comprising 6-13 atoms that can be optionally annelated with at least one (C5-C7)-carbocycle and/or possibly annelated with heterocycle comprising 4-10 atoms in ring and comprising at least one heteroatom chosen from oxygen (O), sulfur (S) or nitrogen (N) atom; Ra 1 represents a substitute of amino group but not hydrogen atom, such as substituted (C1-C6)-alkyl, possibly substituted aryl and possibly substituted 5-10-membered heterocyclyl comprising at least one heteroatom chosen from O, S or N; Rb represents carbamoyl group -C(O)NHRa wherein Ra represents a substitute of amino group but not hydrogen atom, such as possibly substituted alkyl, possibly substituted aryl, possibly substituted 5-10-membered heterocyclyc comprising at least one heteroatom chosen from O, S or N; Rc represents a substitute of cyclic system, such as possibly substituted (C1-C6)-alkyl, possibly substituted aryl and possibly substituted 5-6-membered heterocyclyl comprising at least one heteroatom chosen from O, S or N; or Rb and Rc form in common aminocyanomethylene group [(=C(NH2)CN], or their pharmaceutically acceptable salts. Also, invention relates to methods for synthesis of these compounds (variants), a pharmaceutical composition, combinatory and focused libraries.
Analogs of himbacin, their using and pharmaceutical composition based on thereof possessing property of thrombin receptor antagonist / 2319704
Invention relates to heterocycle-substituted tricyclic compounds of the formula (I): or their pharmaceutically acceptable salts wherein R means hydrogen atom; R1 and R2 are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R3 means hydrogen atom; n1 and n2 = 0-3 independently under condition that they both do not mean 0; Het means pyridyl wherein pyridyl is added to B through cyclic carbon atom and it comprises from 1 to 4 substitutes (W) chosen independently from group comprising -NR4R5, -NHCOR26, -NHSO2R16; R21 means aryl and R21 means heteroaryl wherein heteroaryl represents furyl, thienyl, pyridyl, thiazolyl, pyrrolidinyl, azethidinyl; R4 and R5 mean hydrogen atom or alkyl comprising 1-6 carbon atoms, or R4 and R5 mean in common -(CH2)3-, -(CH2)4-, -(CH2)5- or -(CH2)2NR7-(CH2)2- wherein R7 means hydrogen atom or alkyl comprising 1-6 carbon atoms; R8, R, R10 and R11 mean hydrogen atom; B means -(CH2)n4CR12=CR12a(CH2)n5 wherein n4 and n5 = 0-2 independently; R12 and R12a are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R21 means from 1 to 3 substitutes chosen independently from group comprising hydrogen atom, trifluoromethyl, trifluoromethoxy, halogen atom, cyano, alkyl comprising 1-6 carbon atoms, alkoxy group comprising 1-6 carbon atoms, or -CR29(=NOR28); R22 means -COR23, -S(O)R31, -S(O)2R31 or -COOR27; R23 means cycloalkyl comprising 3-7 carbon atoms, (C3-C7)-cycloalkyl-(C1-C6)-alkyl, cycloalkyl comprising 3-7 carbon atoms containing from 1 to 3 substitutes chosen from group comprising halogen atom, (C1-C3)-alkoxy-(C1-C3)-alkyl, hydroxy group and alkoxy group comprising 1-6 carbon atoms, aryl, aryl-(C2-C6)-alkyl; R27 means alkyl comprising 1-6 carbon atoms, phenyl or benzyl; R28 and R29 are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R31 means alkyl comprising 1-6 carbon atoms, halogenalkyl comprising 1-6 carbon atoms, aryl, aryl-(C1-C6)-alkyl. Also, invention relates to pharmaceutical compositions containing these substances and their using for preparing a drug used in treatment of thrombosis, atherosclerosis, restenosis, hypertension, stenocardia, arrhythmia, heart failure and cancer.
|
FIELD: chemistry. SUBSTANCE: invention relates to a method for synthesis of 4β-amino-4'-demetyl-4-desoxypodophyllotoxin of formula (1), involving the following steps: a) reaction of thiourea and 4β-halogenoacetamido-4'-demethyl-4-desoxypodophyllotoxin in a medium of a weak pure acid or mixture of acid, water an organic solvent without using any other solvent at temperature higher than ambient temperature; b) extraction of 4β-amino-4'-demethyl-4- desoxypodophyllotoxin. EFFECT: compound is an intermediate product in synthesis of anti-cancer compounds. 22 cl, 1 tbl, 1 ex
The technical field to which the invention relates. The present invention relates to a method for producing 4β-amino-4'-demethyl-4-methoxymethylethoxy formula 1 of 4β-halogenoacetyl-4 demethyl-4-methoxymethylethoxy formula 3 (X=Cl, Br or I) splitting in the presence of thiourea and acid. In particular, the invention concerns a method of obtaining 4β-amino-4'-demethyl-4-methoxymethylethoxy formula 1 of 4'-demethylepipodophyllotoxin formulas 2 through 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy formula 3 (X=Cl, Br or I). The level of technology 4β-amino-4'-demethyl-4-methoxymethylethoxy is a synthetic intermediate compound used in the production of anti-cancer compounds (application for French patent No. 0404053). Technology of production of this intermediate compound is based on the conversion of 4'-demethylepipodophyllotoxin (formula 2) 4β-azido-4'-demethyl-4-methoxymethylethoxy formula 4, followed by catalytic oxidation of this derived azide to amine derivative of formula 1. The problem with this transformation is the lack of stereoselectivity conversion of the activated derivative at position 4 (pasilabinimo), providing a mixture of azides α and β of formula 4. This problem is partially solved through the use of sodium azide and triperoxonane acid, see J. Med. Chem. 1991, No. 34, str. However, you need to clean the intermediate connection azide of formula 4 using chromatography, and the product by catalytic reduction, i.e. amine of formula 1. Another method disclosed in Chinese Chemical Letters, 1993, No. 4 (4), str. These authors use the method with the use of azide by reaction between the nitrogen-hydrogen acid HN3(prepared in situ) in the presence of epirate BF3at -10~-15°C. Obtained by these authors, the results indicate a high stereoselectivity transformation ratio output not less than 80%. The method of conversion of the azide of formula 4 in the amine of formula 1 is described in Tet. Let., 1999, No. 40, str and Tet. Let., 2000, str. These authors applied the samarium iodide in t-BuOH and THF (tetrahydrofuran) or in a double connection FeSO4·7H2O/NH3. Recently, a confirmation message prompts you to clean chromatography, Bioorg. Med. Chem., 2003, No. 11, str. The authors have obtained amine of formula 1 when the yield factor of 70%. However, these methods create two problems: 1) the use of hazardous derived azide, which is potentially explosive, especially when used in large mass is Taba in industrial production of medicaments; 2) the need for one or even two stages chromatography to obtain compound "Amin" formula 1 high quality to produce the target product, namely anti-cancer drug, which are costly steps in industrial scale production. Disclosure of inventions The present invention is to solve both of these problems, i.e. removal of hazardous or explosive compounds and stages of purification by chromatography. 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy, which is an intermediate compound of formula 3, is a known compound (application for French patent No. 0404053, WO 2004/073375). Also known transition of the compounds of formula 2 to the compound of formula 3 (application for French patent 0404053). Therefore, an object of the invention is the method of synthesis of compounds of formula 1 from the compound of formula 3. In traditional organic synthesis splitting chloracetamide to obtain amines are produced by processing the derived chloracetamide tertiary amide-thiourea in ethanol in the presence of acetic acid at the optimum ratio of 5:1 (A.Jirgensons and other Synthesis, 2000, str). When this reaction is applied ethanol and acetic acid does not contain water. This method has never been used for a number of podophylla oxine and for this it is not suitable. Indeed, as applied in the case of the compound of formula 3, this method results in 10 hours at reflux distilled to convert less than 10% of the source material (the compound of formula 3), and the reaction intermediate compound (X=S - isothiouronium in the form of chloride) is no longer reacts (see comparative example). A longer reaction time is unfavorable from the viewpoint of purity, which is so formed as secondary products. It took the adaptation and improvement of methods to achieve the required conversion. Unexpectedly, the inventors have established a method for the synthesis of the compounds of formula 1 from the compound of formula 3, which allows to obtain the compound of formula 1 with a high degree of purity without additional purification steps (in particular, chromatography). The object of the invention is a method for the synthesis of 4β-amino-4'-dimethyl-4-methoxymethylethoxy formula 1: characterized in that it comprises the following successive stages: a) carrying out the reaction in an environment of weak net acid without another solvent at a temperature above ambient temperature, between thiourea and 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy formula 3: where: X represents a halogen atom selected the CSOs from the group consisting of chlorine, bromine and iodine, preferably chlorine; b) removing 4β-amino-4'-demethyl-4-methoxymethylethoxy. In respect of the method of splitting chloracetamide described in the prior art (A.Jirgensons etc., Synthesis, 2000, str), it was found that this operation can be carried out in a pure weak acid, i.e. without the presence of water or an organic solvent. In the sense of the present invention the use of the term "acid" goes back to its definition on Bronsted (Bronsted), namely it is a chemical substance that can lose a proton H+. A weak acid is an acid, which is in contrast to the strong acid is not dissociated completely in the water. A weak acid is characterized mainly by the pH value from 4 to 6 at 25°C. In particular, a weak acid is predominantly carboxylic acid of formula 5, R-COOH, where R is a hydrogen atom or an alkyl radical with 1 or 2 carbon atoms. More severe acid now not used as a solvent, they do not have acceptable pouchetii (in particular, butyric acid). In particular, the weak acid is selected from the group consisting of formic, acetic or propionic acid, preferably acetic acid. The following relations between the different compounds correspond to sootnosheniyami, used for these compounds, unless otherwise specified. In the framework of the present invention, the expression "pure weak acid" means that the acid is glacial, i.e. not containing water. The expression "without another solvent" means that the reaction medium in step a) contains only pure weak acid, the compound of formula 3 and thiourea, therefore, it does not contain water or another solvent, such as alcohol or an organic solvent. At the step a) reaction medium is preferably heated to temperatures above 60°C, more preferably to a temperature of from 60 to 100°C. Another characteristic of the invention is that used pure weak acid serves as a solvent during the reaction. The molar ratio between 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy and a weak acid is not less than 0.5. The molar ratio between 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy and thiourea is preferably from 0.5 to 1. According to the optimal execution of the invention in step a) 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy lead in contact with a pure weak acid before the addition of thiourea. Another, better option 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy and pure weak acid is that are in contact with one another, and 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy is preferably in suspension in pure weak acid, and the reaction medium is heated to the desired temperature before the addition of thiourea at this temperature. The duration of the reaction in stage a) is preferably from 1 to 3 hours. In case of use of pure acetic acid duration of the reaction in step a) is about 2 hours. At the end of step a) target product formula 1 precipitates in the reaction medium. It is extracted in the step (b) any known to the average expert way, in particular, a simple filtration and drying by conventional methods are sufficient. After filtering and drying in the usual way compound of formula 1 in the form of hydrochloride, bromhidrosis or hodgert get with an average molar yield of over 85%, preferably more than 90% of the molar amount of the compounds of formula 3. In case of use of pure acetic acid compound of formula 1 in the form of hydrochloride, bromhidrosis or hodgert get with an average molar yield of 93% of the molar amount of the compounds of formula 3. The compound of formula 1 is preferably obtained when the degree of purity of more than 90%, more preferably 95% or more. The compound of formula 1 obtained in the form of hydrochloride, bromhidrosis or is oggidata, is clean and does not require an additional step of purification by chromatography. It can be directly used in the subsequent steps of the synthesis, which is a significant advantage from the standpoint of cost-effective production on an industrial scale. The object of the present invention is also a method for the synthesis of 4β-amino-4'-demethyl-4-methoxymethylethoxy formula 1: characterized in that it comprises the following successive stages: i) carrying out the reaction in a mixture of acid, water and an organic solvent at a temperature above the ambient temperature between thiourea and 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy formula 3: where X means a halogen atom selected from the group consisting of chlorine, bromine and iodine, preferably chlorine; ii) removing 4β-amino-4'-demethyl-4-methoxymethylethoxy. In respect of the method of splitting chloracetamide disclosed in the prior art (A.Jirgensons etc., Synthesis, 2000, str), it was found that adding water to the reaction environment contributes to the reaction, accompanied by complete consumption of starting material without the formation of degradation products. Preferably, the reaction medium did not contain any other solvent and reagent. In phase i), the reaction medium is preferably heated to a temperature above 60°C, more preferably to a temperature of from 60 to 100°C. the Molar ratio of 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy and timesaving is preferably from 0.5 to 1. In phase i) 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy preferably brought into contact with a mixture of acid, water and an organic solvent before the addition of thiourea. More optimally, when 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy and a mixture of acid, water and an organic solvent will result in contact between them, while preferably, 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy were suspended in the above-mentioned mixture, and the reaction medium is heated to the desired temperature before the addition of thiourea at this temperature. Preferably, the organic solvent used in the second method according to the invention, represented a water-soluble organic solvent, more preferably, to be selected from the group consisting of cyclic ethers, in particular dioxane, alcohols, in particular methanol, ethanol, propanol and isopropanol, and N,N-dimethylacetamide, dimethylformamide and N-methylpyrrolidone. p> Thus, in relation to the method of splitting described in the prior art (A.Jirgensons etc., Synthesis, 2000, str), it was also found that the operation can be carried out in the presence of an organic solvent, such as dioxane or N,N-dimethylacetamide, instead of ethanol in the presence of water.In the first preferred embodiment of the second method according to the invention the organic solvent is an alcohol, preferably ethanol. Under this first option, the acid is preferably a strong acid, in particular selected from the group consisting of hydrochloric, sulfuric and phosphoric acids. The volume ratio of alcohol/water + strong acid) is preferably 2-5:0.5 to 2, more preferably of 2.5:1, with a strong acid has a normality of from 1 to 2. The compound of formula 1 is preferably obtained with a molar yield of over 80%, more preferably more than 85%, in particular 90%. The duration of the reaction is preferably more than 8 hours but less than 10 hours, more preferably about 9 hours. The compound of formula 1 also preferably be obtained with purity of over 90%, in particular 95%. Alternatively, in the first option, preferably use a weak acid, in particular carboxylic acid of formula 5, R-COOH, where R is a hydrogen atom or alkylpyridine with 1-2 carbon atoms. More severe acid now not used as solvents and do not have acceptable properties pouchetti (in particular, butyric acid). In particular, the weak acid is selected from the group consisting of formic, acetic or propionic acid, preferably acetic acid. The volume ratio of alcohol/water/weak acid is preferably 2-10:0.5 to 2:0.5 to 2, more preferably 5:1:1. In particular, the volume ratio of ethanol/water/acetic acid is preferably 5:1:1. The compound of formula 1 are preferably in a molar yield of more than 55%, preferably 60%. The duration of the reaction is preferably more than 8 hours but less than 11 hours, more preferably about 10 hours. The compound of formula 1 are preferably in a purity of more than 90%, in particular 95%. In the second preferred embodiment of the second method according to the invention the organic solvent is a cyclic simple ether, in particular dioxane, N,N-dimethylacetamide, dimethylformamide and N-organic. The volume ratio of the cyclic simple ether (dioxane) or N,N-dimethylacetamide, dimethylformamide and N-organic/water/weak acid (acetic acid) is preferably 2-10:0.5 to 2:0.5 to 2, more preferably 5:1:1. The volumetric ratio of dioxane or N,N-dimethylacetamide dimethylformamide and N-organic/water/acetic acid is preferably 5:1:1. The compound of formula 1 is preferably obtained when the molecular output of more than 60%, more preferably more than 65%, in particular 70%. The duration of the reaction was preferably more than 4 hours but less than 10 hours, more preferably about 5-6 hours. The compound of formula 1 is preferably obtained with a purity of more than 90%, preferably 95%. In the studied cases, the desired product precipitated in the reaction medium. It was removed in step b) by any known to the average expert way, in particular, a simple filtration and drying by known methods are sufficient. The obtained compound of formula 1 in the form of hydrochloride, bromhidrosis or hodgert was clean and did not require additional purification step chromatography. It can be used directly in the subsequent steps of the synthesis, providing a significant advantage from the standpoint of cost-effective production on an industrial scale. Within the first or second method according to the invention 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy formula 3 receive preferably the reaction between the 4'-demethylepipodophyllotoxin formula 2: and halogenoacetyl formula 6 X-CH2- C≡N, where X means a halogen atom selected from the group consisting of chlorine is, bromine and iodine, in an acidic environment. This is followed by a Ritter reaction for the direct capture of 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy crystallization at the end of the reaction when the ratio of the output preferably more than 80%, more preferably more than 90%. This intermediate compound possesses exclusively the β stereochemistry on the carbon atom in position 4. At this stage the problem of stereochemistry. Purity specified intermediate compounds is that this connection can be used without additional purification phase splitting to receive 4β-amino-4'-demethyl-methoxymethylethoxy formula 1. 4'-demethylepipodophyllotoxin formula 2 (obtained by the method described in French patent No. 2742439) is preferably treated with chloroacetonitrile, regular and cheap reagent, together with sulfuric acid. Therefore, 4β-chloroacetamido-4'-demethyl-4-detoxicification preferably obtained when the ratio of the yield of 93%. After filtering and drying in the usual way compound of formula 1 in the form of hydrochloride, bromhidrosis or hodgert receive as a result of applying ice pure acetic acid (without water and other organic solvent, the first method according to the invention) with an average molar yield of 86% of the molar amount of 4β-demethylepipodophyllotoxin is a (formula 2), i.e. in two stages (from compounds of formula 2 to the compound of formula 3, then from the compounds of formula 3 to the compound of formula 1). The implementation of the invention The following examples show methods used. Example 1. Getting 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy (formula 3) In a suspension of 30 g (0,075 mol) of 4'-demethylepipodophyllotoxin 47.5 ml of 0.75 mole) of chloroacetonitrile add drops of 0.5 ml of concentrated sulfuric acid at ambient temperature. Shaken for one hour at the same temperature, while watching the dissolution and re-precipitation. Add 300 ml of 2-propanol. The precipitate is filtered, washed with 200 ml of 2-propanol and water until pH 7. The obtained solid white dried in vacuum at 40°C and received from 32.9 g of compound chloracetamide formula 3. The molar yield was 93%. Melting point F 240°C. The NMR analysis of the proton:1N Yarm (DMSO) δ 8,65 (d, 1H, J=7 Hz, NH), compared to 8.26 (s, 1H, 4'-OH), 6,78 (s, 1H, H5), is 6.54 (s, 1H, H8), 6,24 (s, 2H, H2'N6'), of 5.99 (d, 2H, J=11.3 Hz, OCH2O)to 5.17 (dd, 1H, J=4,56 and 7 Hz, H4), 4,51 (d, 1H, J=5,2 Hz, H1), the 4.29 (t, 1H, J=8 Hz, H11a), 4,10 (s, 2H, CH2Cl), of 3.97 (m, 1H, H3), of 3.78 (dd, 1H, J=8 Hz and 10 Hz, H11b), 3,63 (s, 6H, 2×och3)and 3.15 (dd, 1H, J=5,2 and 14 Hz, H2). Other halogenoacetyl (X=Br, I) can be the ü obtained similarly using bromoacetonitrile or idatetime. Comparative example. Getting 4-amino-4'-demethyl-4-methoxymethylethoxy (formula 1). Method using ethanol/acetic acid 5:1 (Synthesis, 2000, str). Table 1: experiment 1. A suspension of 0.5 g (1.05 mmole) 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy obtained in example 1 in a mixture of 2.5 ml of ethanol and 0.5 ml of glacial acetic acid is brought to 80°C with shaking. Once imposed 0.12 g (of 1.57 mmole) of thiourea. Shaken at this temperature for 10 hours. Analysis of the reaction medium thin-layer chromatography showed the presence of only less than 10% of the desired product 4β-amino-4'-demethylepipodophyllotoxin (formula 1) from the present intermediate isothiouronium (X=S-isothiouronium), which is entered into the reaction, and the products of decomposition. Example 2. Getting 4β-amino-4'-demethyl-4-methoxymethylethoxy (formula 1). Method with the use of pure glacial acetic acid, the first method according to the invention. Table 1: experiment 2. A suspension of 17 g (0,0358 mole) 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy obtained in example 1 in 75 ml of glacial acetic acid is heated to 80°C with shaking. Add once 4,2 g (0,0537 mole) of thiourea. At this temperature, shaken for 1.5 hours, while watching the dissolution and re-precipitation. R is the promotional environment is filtered in the hot state, washed with 75 ml of glacial acetic acid and diisopropyl ether. The obtained solid white dried in vacuum at 40°C. the Obtained 14.6 g of the compounds of formula 1 in the form of a hydrochloride in a molar yield of 93%. Melting point F was more than 260°C. The NMR analysis of the proton:1N Yarm (DMSO) δ 8,63 (m, 2H), 8,32 (m, 1H), 7.23 percent (s, 1H, H5), 6,60 (s, 1H, H8), 6,18 (s, 2H, H2'N6'), equal to 6.05 (d, 2H, J=2.1 Hz, och2About), to 4.73 (d, 1H, J=4.5 Hz, H4), 4,56 (d, 1H, J=5,2 Hz, H1), 4,34 (m, 2H, H11aand H11b), the 3.65 (dd, 1H, J=5,2 Hz, H2), 3,62 (s, 6H, 2×och3), 3,06 (m, 1H, H3). Example 3. Getting 4β-amino-4'-demethyl-4-methoxymethylethoxy (formula 1). Method using ethanol and hydrochloric acid 1N, the second method according to the invention, the first option, the first alternative. Table 1: experiment 3. A suspension of 0.5 g (1.05 mmole) 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy obtained in example 1 in a mixture of 2.5 ml of ethanol and 1 ml of 1N hydrochloric acid is heated to 80°C with shaking. Once added 0.12 g (of 1.57 mmole) of thiourea. When the specified temperature is shaken for 9 hours to see the dissolution and re-precipitation. The cooled reaction medium is filtered, washed with ethanol and diisopropyl ether. The obtained solid white dried in vacuum at 40°C. the Obtained 0.4 g of the compound is ormula 1 in the form of a hydrochloride in a molar yield of 90%. Melting point F amounted to over 260°C. Example 4. Getting 4β-amino-4'-demethyl-4-methoxymethylethoxy (formula 1). Method using ethanol/water/acetic acid (5:1:1), the second method according to the invention, the first option, the second option. Table 1: experiment 4. A suspension of 0.5 g (1.05 mmole) 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy obtained in example 1 in a mixture of 2.5 ml of ethanol, 0.5 to water and 0.5 glacial acetic acid is heated to 80°C with shaking. Once added 0.12 g (of 1.57 mmole) of thiourea. At the same temperature was shaken for 10 hours, while watching the dissolution and re-precipitation. The cooled reaction medium is filtered, washed with ethanol and diisopropyl ether. The obtained solid white dried in vacuum at 40°C. the Obtained 0.27 g of the compound of formula 1 in the form of a hydrochloride in a molar yield of 60%. Melting point F amounted to over 260°C. Example 5. Getting 4β-amino-4'-demethyl-4-methoxymethylethoxy (formula 1). Method using solvent (N,N-dimethylacetamide, dioxane)/water/acetic acid, the second method according to the invention, the second option. Table 1: experiment 5. A suspension of 0.5 g (1.05 mmole) 4β-chloroacetamido-4'-demethyl-4-methoxymethylethoxy obtained in example 1 in a mixture of 2.5 ml of dioxane or N,N, 0.5 ml water and 0.5 ml of glacial acetic acid is heated to 80°C with shaking. Once added 0.12 g (of 1.57 mmole) of thiourea. When the specified temperature is shaken for 5-6 hours, while watching the dissolution and re-precipitation. The cooled reaction medium is filtered, washed with 2-propanol and diisopropyl ether. The obtained solid white dried in vacuum at 40°C. the Obtained 0.31 g of compounds of formula 1 in the form of a hydrochloride in a molar yield of 70%. Melting point F amounted to over 260°C. The results of the experiments obtained in the comparative example and in examples 2-5, presented in the following table 1. Table 1 shows a significant advantage, and it does so in the case of use of pure glacial acetic acid at 80°C during the short duration of the reaction, 2 h, to obtain the desired product with excellent yield coefficient with providing very satisfactory purity for subsequent use in the synthesis of anticancer compounds. 1. The method of synthesis of 4β-amino-4'-demethyl-4-methoxymethylethoxy formula 1 2. The method according to claim 1, in which the pure weak acid is a carboxylic acid of formula 5 R-COOOH, where R is a halogen atom or an alkyl radical with 1 to 2 carbon atoms, in particular acetic acid. 3. The method according to claim 1 or 2, wherein in step a) the reaction medium is heated to a temperature of from 60 to 100°C. 4. The method according to claim 1 or 2, in which step a) 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy lead in contact with a pure weak acid before the addition of thiourea. 5. The method according to claim 3, in which step a) 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy lead in contact with a pure weak acid before the addition of thiourea. 6. The method according to claims 1, 2 or 5, in which the duration of the reaction in step a) is from 1 to 3 p.m. 7. The method according to claim 3, in which the duration of the reaction in step a) is from 1 to 3 p.m. 8. The method according to claim 4, in which the duration of the reaction in step a) is from 1 to 3 p.m. 9. The method of synthesis of 4β-amino-4'-demethyl-4-methoxymethylethoxy formula 1 10. The method according to claim 9, in which step (i) reaction medium is heated to a temperature of 60-100°C. 11. The method according to claim 9 or 10, in which in step i) 4β-halogenoacetyl-4'-demethyl-methoxymethylethoxy brought into contact with a mixture of acid, water and an organic solvent before the addition of thiourea. 12. The method according to claim 9 or 10, in which the organic solvent is a water-soluble organic solvent, preferably selected from the group consisting of cyclic ethers, in particular dioxane, alcohols, in particular ethanol, and N,N-dimethylacetamide, dimethylformamide, N-methylpyrrolidone. 13. The method according to claim 11, in which the organic solvent is a water-soluble organic solvent, preferably selected from the group consisting of cyclic ethers, in particular dioxane, alcohols, in particular ethanol, and N,N-dimethylacetamide, dimethylformamide, N-methylpyrrolidone. 14. The method according to any of p, 10, or 13, in which the solvent is ethanol. 15. The method according to claim 11, in which the solvent is ethanol. 16. The method according to item 12, in which the solvent is ethanol. 17. The method according to 14, in which the acid is a strong acid, selected in particular from the group consisting of hydrochloric, sulfuric and phosphoric acids. 18. The method according to item 15 or 16 in which the acid is a strong acid, selected in particular from the group consisting of hydrochloric, sulfuric and phosphoric acids. 19. The method according to claim 9, in which the acid is a weak acid, in particular, carboxylic acid of formula 5, R-COOH, where R means a hydrogen atom, an alkyl radical with 1 to 2 carbon atoms, preferably acetic acid. 20. The method according to claim 20, in which the volumetric ratio of ethanol or dioxin or N,N-dimethylacetamide, dimethylformamide, N-organic : water : acetic acid is 5:1:1. 21. The method according to claim 1 or 9, in which the molar ratio between 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy and thiourea is 0.5-1. 22. The method according to claim 1 or 9, in which 4β-halogenoacetyl-4'-demethyl-4-methoxymethylethoxy formula 3 is obtained by reaction between 4'-demethylepipodophyllotoxin formula 2
|
© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English. |